A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

2016284 citationsJournal Articlehybrid Open Access

Authors

Karen L. Reckamp · City of Hope

Vladislava O. Melnikova

Chris Karlovich · Clovis Oncology (United States)

Lecia V. Sequist · Massachusetts General Hospital

D. Ross Camidge · University of Colorado Denver

Heather A. Wakelee · Stanford University

M. Pérol · Hospices Civils de Lyon

Abstract

DNA derived from NSCLC tumors can be detected with high sensitivity in urine and plasma, enabling diagnostic detection and monitoring of therapeutic response from these noninvasive "liquid biopsy" samples.

Topics & Keywords

Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics Medical Imaging Techniques and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Thoracic Oncology

Volume 11, Issue 10, pp. 1690-1700

DOI: 10.1016/j.jtho.2016.05.035

Field-Weighted Citation Impact: 35.11